Verily has rapidly ramped up its work in healthcare and research in the past two years with new initiatives and new hires. Leveraging its technology capabilities, Verily, a subsidiary of Alphabet and ...

The Alphabet-owned healthcare unit Verily is laying off more than 200 staff, about 15% of the workforce. The cuts were announced in a memo to staff sent on Wednesday. CEO Stephen Gillett said the ...

More than 1,300 oncology drugs are in the development pipeline, waiting to potentially embark on the long journey toward their commercial debut. This journey is usually an arduous one, made even more ...

The symptoms of post-traumatic stress disorder include uncontrolled memories of a traumatic event, anxiety and panic—“hyperarousal” is the technical term—depression, avoiding anything that’s a ...

Alphabet's life science offshoot Verily announced it had raised $1 billion in an investment round led by its parent company alongside a shakeup of its executive team. The company's founder Andy Conrad ...

Alphabet’s life science subsidiary Verily is working to detach itself from Google’s technology and possibly move outside its parent company, according to reporting by Insider. The plan, internally ...

Alphabet's life sciences research arm Verily received FDA 510(k) clearance for its Study Watch to offer an irregular pulse monitor feature. Verily plans to leverage this new capability to detect ...

For Alphabet’s Verily, O is for OneOncology. The two companies have partnered up to accelerate cancer clinical trials. OneOncology, which brings together independent oncology practices, will integrate ...

It’s a make-or-break moment for Verily, as the sprawling Google offshoot rapidly accelerates its strategy to take its most promising products and turn them into tools that not only transform medicine, ...

SAN FRANCISCO — Andy Conrad, the CEO of Verily, the life sciences unit of search engine giant Alphabet, had some headhunting advice at the J.P. Morgan Healthcare Conference last week: use Alphabet’s ...

Verily, Alphabet’s life sciences group, is investing big in developing technologies for the millions of people worldwide with diabetes. Verily announced today that it is teaming up with pharmaceutical ...

The Google spin-off Verily is looking to expand its clinical-trials business. Dr. Amy Abernethy, Verily's new president of research, shared the vision for 2022 in an interview. The venture will sell ...